BBNX Company Profile and Key Details

NASDAQ : BBNX

Beta Bionics

$10.92

0.05+0.46%

Open: 3:18 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Beta Bionics, Inc. (BBNX) stock surged +0.46%, trading at $10.92 on NASDAQ, up from the previous close of $10.87. The stock opened at $10.90, fluctuating between $10.60 and $11.26 in the recent session.

Stock Snapshot

10.87

Prev. Close

484.65M

Market Cap

10.595

Day Low

-6.03

P/E Ratio

-1.81

EPS (TTM)

N/A

Cash Flow per Share

10.9

Open

44.38M

Number of Shares

11.26

Day High

75.35%

Free Float in %

N/A

Book Value

405.66K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 09, 2026	10.40	10.91	10.06	10.87	1.61M
Mar 06, 2026	10.92	11.09	10.44	10.61	906.86K
Mar 03, 2026	12.21	12.42	11.50	11.57	1.61M
Mar 02, 2026	12.39	12.67	12.06	12.52	1.31M
Feb 27, 2026	12.83	12.98	12.39	12.63	684.64K
Feb 26, 2026	12.95	13.15	12.73	13.02	1.05M
Feb 25, 2026	13.19	13.40	12.62	12.89	1.25M
Feb 24, 2026	13.55	14.13	12.90	13.39	998.46K
Feb 23, 2026	13.56	14.00	13.53	13.76	607.04K
Feb 20, 2026	13.70	14.03	13.11	13.70	1.01M
Feb 19, 2026	13.81	13.81	12.77	13.46	859.05K
Feb 18, 2026	12.89	14.05	11.33	13.61	4.07M
Feb 17, 2026	13.90	14.38	13.45	13.97	1.47M
Feb 13, 2026	13.52	14.40	13.25	13.94	729.26K
Feb 12, 2026	14.42	14.75	13.54	13.55	542.43K
Feb 11, 2026	14.74	14.80	13.90	14.12	1.32M
Feb 10, 2026	14.21	15.53	14.13	14.78	1.09M
Feb 09, 2026	13.69	14.04	12.71	13.87	1.1M
Feb 06, 2026	13.47	13.66	12.90	13.08	1.29M
Feb 05, 2026	14.09	14.67	13.17	13.24	873.66K

Contact Details

Irvine, CA 92618

United States

https://www.betabionics.com 949 427 7785

About Company

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.

Stock Peers

PARK

-1.04-5.30%

Park Dental Partners, Inc. Common Stock$18.60 KDLY

0.13+1.16%

Kindly MD, Inc.$11.30 CV

-0.02-0.39%

CapsoVision, Inc.$5.10 PFSA

0.0029+0.33%

Profusa, Inc. Common Stock$0.89 NAKA

-0.0055-2.09%

Nakamoto Inc.$0.26

Company Overview

Beta Bionics, Inc. (NASDAQ:BBNX) closed at $10.92 USD, gaining $0.05 (0.46%) from the previous close of $10.87. The stock is currently mid-range between its 52-week high and low $8.89 and $32.71. With a market capitalization of about $484.65 million, Beta Bionics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~5.60). Key stats such as the average daily volume over the past year has been around 1.30 million shares, volume is running light vs its 52-week average. Headquartered in Irvine, CA, Beta Bionics, Inc. operates in the Healthcare sector and the Medical - Equipment & Services industry. Led by CEO Sean T. Saint, the company employs approximately 352 people and listed since January 30, 2025. Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.

Technical Performance

BBNX has shown mixed momentum, gaining 4.42% over the past week and -7.94% over the past quarter, though year-to-date performance is down -39.51%. Short-term trend indicators are mixed aligned (SMA20 -5.4%, SMA50 -35.95%, SMA200 -35.63%). The stock’s 14-day RSI is 31.64 (weak momentum), while the ATR of 1.23 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -60.2% below its high and over 46.46% above its low. Average 10-day trading volume of 1.36 million shares is in line with the 3-month average of 1.24 million, indicating normal recent market interest.

Valuation Metrics

Beta Bionics, Inc. trades at a P/E ratio of -5.72, slightly below the S&P 500 average, with a price-to-sales ratio of 4.57 and a price-to-book ratio of 1.46 suggesting the stock is closer to book value. The P/FCF stands at -10.04, also above market averages.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 7.91% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 14 Buy ratings, 4 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $40.00 to $16.00. The high target offers 267.99% upside. The low target suggests 47.19% downside. The mean target is $27.26. This offers 150.78% upside. Beta Bionics, Inc. earnings surprise history is a mixed track record. The quarter that ended October 28, 2025, missed forecasts by -26.67%. The prior quarter beat by -23.53%. Over the last six quarters, Apple has recorded several small beats. These include 333.33% in March 25, 2025.

Shareholding & Insider Activity

Beta Bionics, Inc. has 43.47 million shares outstanding. The public float is 23.70 million shares, elevated short interest at 16.58% of float. This equals 6.38 million shares. The short ratio is 5.77 days. Institutional investors hold 123.38% of the float. Insiders own 10.42%. Saint Sean holds 437.81 thousand shares, Mensinger Mike has 188.79 thousand shares and Russell Steven Jon has 179.10 thousand shares. Over the past six months, insider transactions show net selling. They sold 39.07 thousand shares across 18 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Beta Bionics has not generated any revenue.
On valuation metrics, Beta Bionics trades at a P/E of -5.72, P/S of 4.57 and P/B of 1.46. The current ratio is 8.66 and quick ratio is 7.96. Operationally, the company’s inventory turnover is 2.06 and cash conversion cycle is 198.84 days. Debt-to-equity is 0.03, supported by a cash flow-to-debt ratio of -5.79.

Price Forecast & Outlook

Our AI price prediction model suggests that Beta Bionics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -9.84%, with price expected at $9.80 by March 23, 2026, within a range of $9.07 to $10.44 3-Month Outlook: Projected rise of 7.27%, reaching $11.66 by June 05, 2026, with a range of $11.09 to $12.23. 1-Year Outlook: Projected gain of 153.45%, with price at $27.55 by March 09, 2027, within a range of $27.01 to $28.39.

Key Takeaways

Beta Bionics, Inc. (NASDAQ:BBNX) shares are down -39.51% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Beta Bionics, Inc. trading at a premium to the broader market with a P/E of -5.72. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $27.12, suggesting 149.49% upside. Our AI forecast model points to short-term weakness (-9.84% over two weeks), a medium-term rise (7.27% over three months), and a longer-term gain (153.45% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Beta Bionics, Inc. (BBNX) stock price?

Beta Bionics, Inc. (NASDAQ: BBNX) stock price is $10.92 in the last trading session. During the trading session, BBNX stock reached the peak price of $11.26 while $10.60 was the lowest point it dropped to. The percentage change in BBNX stock occurred in the recent session was 0.46% while the dollar amount for the price change in BBNX stock was $0.05.

BBNX's industry and sector of operation?

The NASDAQ listed BBNX is part of Medical - Equipment & Services industry that operates in the broader Healthcare sector. Beta Bionics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of BBNX?

No Data

How BBNX did perform over past 52-week?

BBNX's closing price is 22.27% higher than its 52-week low of $8.89 where as its distance from 52-week high of $32.71 is -66.77%.

How many employees does BBNX have?

Number of BBNX employees currently stands at 352.

Link for BBNX official website?

Official Website of BBNX is: https://www.betabionics.com

How do I contact BBNX?

BBNX could be contacted at phone 949 427 7785 and can also be accessed through its website. BBNX operates from 11 Hughes, Irvine, CA 92618, United States.

How many shares of BBNX are traded daily?

BBNX stock volume for the day was 405.66K shares. The average number of BBNX shares traded daily for last 3 months was 1.3M.

What is the market cap of BBNX currently?

The market value of BBNX currently stands at $484.65M with its latest stock price at $10.92 and 44.38M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	352
Beta	5.6
Sales or Revenue	N/A
5Y Sales Change%	62.143%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Medical - Equipment & Services

BBNX Company Profile and Key Details

Beta Bionics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Financial & Profitability Overview

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Earnings & Analyst Outlook

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook